MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles (FLEX)

Short Title: FLEX

Enrollment Status: Recruiting

NCT #: NCT03053193

Specialty Area: Oncology

Condition Studied: Breast Cancer

Age Groups: Adult; Older Adult

Phase: Not Applicable

Study Information

Summary / Purpose

To collect information about gene expression testing and clinical outcomes over time to help researchers better understand how tumor biology relates to treatment responses and long-term outcomes. The goal of the study is to create a large database that can support future research and help improve personalized care for people with early breast cancer.

Study Type: Observational

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Newly diagnosed with stage I, II, or III breast cancer
Have had MammaPrint (with or without BluePrint) testing on their tumor

What's Involved

Participation in the study will include:

Consenting to share clinical and gene expression data from standard genomic testing (MammaPrint and BluePrint) for long-term research
No investigational treatment or extra procedures required beyond usual care

Principal Investigator

Lee Schwartzberg, MD

Oncology

A Member of

(775) 982–5000

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT03053193

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews